Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma
Janet E. Murphy(Harvard University), Theodore S. Hong(Massachusetts General Hospital), Thomas F. DeLaney(Massachusetts General Hospital), Keith D. Lillemoe(Harvard University), Lipika Goyal(Stanford Medicine), Cristina R. Ferrone(Cedars-Sinai Medical Center), David P. Ryan(East Carolina University), Jennifer Y. Wo(Massachusetts General Hospital), Lawrence S. Blaszkowsky(Brigham and Women's Hospital), Jeffrey W. Clark(Massachusetts General Hospital), Andrew X. Zhu(Icahn School of Medicine at Mount Sinai), Wenqing Jiang(Waseda University), Eunice L. Kwak(Harvard University), Jill N. Allen(Harvard University), Lorraine C. Drapek(Harvard University), Jason E. Faris(Royal Marsden NHS Foundation Trust), Beow Y. Yeap(Harvard University), Carlos Fernández‐del Castillo(Massachusetts General Hospital)
Cited by 549
Related Papers
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
|Hepatology|2018|4.7k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
AASLD guidelines for the treatment of hepatocellular carcinoma
|Hepatology|2017|4.2k